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While B cells are generally considered to be positive regulators of humoral immune 
responses due to their ability to differentiate into plasmablasts/plasma cells and produce 
antibodies, B cells also modulate immune responses through antigen presentation and 
cytokine secretion. Moreover, “regulatory B cells” that suppress immune responses 
have been recognized as an important new component of the immune system. In mice, 
the function of regulatory B cells is almost exclusively dependent on IL-10. The cell 
surface phenotype of murine IL-10-producing regulatory B cells is reported to be 
CD1dhiCD5+ or CD1dhiCD21hiCD23+IgMhi, and thus their phenotype overlaps with that 
of CD5+ B-1a cells, CD1dhiCD21hiCD23loIgMhi marginal zone (MZ) B cells, and 
CD1dhiCD21hiCD23hiIgMhi T2-MZ precursor B cells. Contrary to earlier work that 
suggested a minor role for B cells in contact hypersensitivity, regulatory B cells are now 
known to have a critical inhibitory functions in this type of immune response. 
Furthermore, studies using murine disease models have demonstrated that regulatory B 
cells play a significant role in autoimmune connective tissue diseases such as 
rheumatoid arthritis and systemic lupus erythematosus, as well as organ-specific 
autoimmune diseases including experimental autoimmune encephalomyelitis and 
inflammatory bowel disease. In comparison to mouse regulatory B cells, little is known 
regarding their human counterparts. One recent study demonstrates that human 
CD19+CD24hiCD38hi B cells possess regulatory capacity. Clarifying the molecular 
mechanisms by which regulatory B cells suppress immune responses will be of great 
benefit in the development of new B cell-targeted therapeutic strategies.  
3 
1. Introduction 
Optimal immune responses are accomplished by balancing the function of “activating” 
subsets and “suppressive” subsets of immune cells. This is most clearly understood for 
T cells, in which effector T cells and regulatory T cells have opposing roles in 
maintaining the delicate balance between host defense, inflammation, and 
autoimmunity. 
Historically, B cells have been characterized as positive regulators of humoral 
immune responses by their ability to differentiate into plasmablasts/plasma cells and 
produce antibodies (Abs). Nonetheless, B-cell suppression of an immune response was 
first described back in 1974 where splenic B cells were found to impair delayed type 
hypersensitivity (DTH) responses in guinea pigs [1]. Recently, however, B cell subsets 
that suppress immune responses, termed “regulatory B cells”, have been recognized as 
an important new component of the immune system [2-5]. Studies have demonstrated 
that regulatory B cells play a major role in various immune responses and diseases, 
from simple contact hypersensitivity to complex systemic autoimmune diseases, and 
that the suppression mediated by regulatory B cells is an important means not only for 
the termination of inflammation but also for the maintenance of peripheral tolerance. 
Identification of the molecular mechanisms underlying regulatory B cell suppression of 
immune responses is of great relevance in the understanding of allergic skin diseases 
and autoimmune diseases, and in the development of new therapeutic strategies. 
 
2. Various functions of B cells  
B cells are classified into two lineages, B-1 and B-2 cells. B-1 cells emerge early in 
development and are abundantly present in the peritoneal and pleural cavities, and are 
defined by the following pattern of surface marker expression: B220lo, IgMhi, IgD+, 
CD9+, CD43+, and CD23lo. B-2 cells are defined phenotypically as B220hi, IgMhi/lo, 
IgD+, CD9-, CD43-, and CD23hi. B-1a cells express CD5, while the B-1b subset does 
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not. B-1 cells are long-lived, self-renewing cells that produce polyreactive IgM known 
as natural Abs, and do not undergo extensive somatic hypermutation. B-2 cells, in 
contrast, are capable of generating hypermutated Abs, and take the central role in the 
conventional adaptive humoral immunity. Immature B-2 cells develop in the bone 
marrow and migrate to the spleen, and are then called transitional B cells (Figure 1). 
Transitional B cells can be further subdivided into two populations, T1 
(IgD–IgM+CD21loCD23–) and T2 (IgDhiIgMhiCD21intCD23+). An additional transitional 
B cell subset termed T3 has been reported, although T3 cells may be anergic, rather than 
precursors of mature, B cells. Transitional B cells maturate into follicular B cells 
(IgDhiIgMloCD21intCD23hi) or marginal zone (MZ) B cells 
(IgMhiIgDloCD21hiCD1dhiCD23lo). Naive follicular B cells encounter antigens (Ags) in 
the secondary lymphoid organs and, in conjunction with cognate T-cell help, become 
activated and proliferate. Activated B cells differentiate into memory B cells or plasma 
cells. In contrast, MZ B cells, another B-2 cell subset, are specialized to reside in the 
splenic marginal sinus, a compartment that samples the blood stream for pathogens. B-1 
and MZ B cells both play important role in the rapid response of the immune system to 
pathogens in the blood as well as the peritoneal and pleural cavities. 
While the hallmark function of B cells is Ab production, B cells have many 
other functions including an ability to serve as antigen presenting cells (APSs) [6-9]. B 
cells are able to internalize immune complexes, present Ag via class II MHC and 
express co-stimulatory molecules, such as CD80, CD86, and OX40L. B cells can also 
produce cytokines in response to a diverse array of stimuli, including microbial products, 
Ags, cytokines, and T cells [10]. The cytokines produced by B cells include interferon 
(IFN)-, interleukin (IL)-4, IL-10, and IL-12. These cytokine-producing effector B cells 
are able to promote the differentiation of naive T cells into Th1/Th2 effectors [11]. 
Furthermore, B cells can influence the Ag-presenting functions of dendritic cells (DCs). 
Thus, in addition to their classic role of producing Abs, B cells can positively regulate 
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immune responses in a multiude of ways. 
Mounting evidence suggests that these non-classical B cell functions are 
critical in the manifestation of several autoimmune diseases. For example, Shlomchik 
and colleagues demonstrated that, in lupus-prone MRL/lpr mice, elimination of B cells 
results in a complete abrogation of nephritis, vasculitis, and skin disease [12]. 
Furthermore, MRL/lpr mice with B cells that cannot secrete Abs still develop nephritis 
and vasculitis. Therefore, these results suggest that, independent of autoantibody 
production, B cells are essential for disease initiation or progression through either APC 
function or secretion of proinflammatory cytokines [12].  
Clinically, this has been demonstrated by the efficacy of B cell-depletion 
therapy in a variety of diseases. B cell-depletion therapy using the anti-CD20 
monoclonal Ab (mAb) Rituximab is beneficial not only in autoantibody-mediated 
diseases but also in other diseases that are not considered to be mediated by Abs, such 
as type I diabetes and multiple sclerosis. Thus, B cells have additional functions outside 
of Ab production, and are likely to play significant roles in autoimmunity. 
 
3. The history of regulatory B cells 
While B-cell functions mentioned above work to augment immune responses, recent 
studies have highlighted the importance of a “new” B cell population, called regulatory 
B cells, that suppresses immune responses. In fact, evidence for the suppressive 
function of B cells was first documented more than 30 years ago. In 1974, Katz, et al. 
demonstrated that column depletion of B cells from splenocyte preparations eliminated 
the ability of adoptively transferred cell preparations to inhibit DTH responses in guinea 
pigs [1]. This finding led to the conclusion that DTH responses and T-cell function can 
be regulated by “suppressor B cells” that are distinct from Ab-producing cells. 
Follow-up studies showed that adoptive transfer of Ag-activated B cells or B-cell blasts 
could induce tolerance in recipient naive mice and induce the differentiation of 
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suppressor T cells [13-15]. In 1983, Kennedy and Thomas, using adoptive transfer of 
dinitrophenyl-human immunoglobulin (DNP-HGG)- primed splenocytes, described the 
differentiation of Ag-specific regulatory B cells able to ablate a secondary anti-hapten 
immune response [16]. 
Despite the availability of these data in the literature, the suppressive role of B 
cells in immune regulation was mostly overlooked for another decade. Subsequently, a 
B cells regulatory effect in autoimmune diseases was reported by Wolf, Janeway, and 
colleagues in 1996 [17]. They observed that B cell-deficient MT mice, immunized 
with myelin basic protein (MBP) peptide in complete Freund’s adjuvant (CFA), suffer a 
much more severe form of experimental autoimmune encephalomyelitis (EAE) than 
wild type mice and do not undergo spontaneous remission. Fillatreau, Anderson, and 
colleagues later demonstrated that the exacerbation of EAE in MT mice is due to a 
deficiency in IL-10-producing B cells [18]. Mizoguchi and Bhan, however, were the 
first to use the term ‘regulatory B cells’ to designate B cells with inhibitory properties [2, 
19]. They reported that, in T-cell receptor (TCR) -deficient mice, which spontaneously 
develop colitis, B-cell deficiency results in an earlier onset of disease and exacerbated 
intestinal inflammation. While they first proposed an Ab-mediated protective 
mechanism since they observed that administration of purified immunoglobulin (Ig) 
from TCR-deficient mice attenuated colitis in TCR-deficient MT mice, they later 
demonstrated that regulatory B cells differentiate in a chronic inflammatory 
environment express high levels of CD1d, produce IL-10, and suppress the progression 
of intestinal inflammation by directly downregulating inflammatory cascades associated 
with IL-1 and STAT3 activation. Mauri et al. also demonstrated a suppressive function 
for IL10-producing B cells in collagen-induced arthritis (CIA) [20]. Thus, regulatory 




4. The characterization of IL-10-producing regulatory B cells 
While earlier studies hypothesized that the suppressive function of regulatory B cells is 
mediated by “neutralizing” Abs, most recent studies are in agreement that this function 
requires IL-10. Thus, in order to characterize regulatory B cells, which B cell subsets 
secret IL-10 is a critical question. IL-10 production is a well-known property of 
peritoneal B-1 cells. Almost 20 years ago, O’Garra and colleagues demonstrated that 
peritoneal CD5+ B cells preferentially produce IL-10 transcripts in response to 
lipopolysaccharide (LPS) stimulation [21, 22]. Among conventional B-2 cells, MZ B 
cells have been found to produce elevated levels of IL-10 upon LPS or CpG stimulation 
[23, 24]. In addition, ligation of CD1d, highly expressed on MZ B cells, induces IL-10 
secretion by some cell types [25]. 
In 2002, Mizoguchi et al. reported that CD1dhiCD21intCD23hiIgMint B cells 
are induced in mesenteric lymph nodes in the TCR-deficient colitis mouse model [19]. 
Inflamed mesenteric lymph node B cells demonstrated IL-10-dependent regulatory 
properties, although individual IL-10-producing B-cell phenotypes were not identified. 
In 2007, using CD19-deficient mice, we found that B cells are important for 
suppressing contact hypersensitivity (CHS)-induced inflammation [26]. CD19 is a 
positive B-cell response regulator which governs intrinsic and stimulant-dependent 
signaling thresholds in B cells [8, 27, 28]. CD19 is a member of the Ig superfamily and 
is expressed only on B cells and follicular DCs. CD19 functions as a specialized adapter 
protein regulating Src-family protein tyrosine kinases, PI3K, and Vav, and thus serves as 
a key regulator of multiple signaling pathways that are crucial for modulating basal and 
BCR-induced signals. Although B cells from CD19-deficient mice are hyposensitive to 
a variety of transmembrane signals, CD19 loss results in increased and prolonged 
reactivity of CHS, which is ameliorated by the adoptive transfer of CD21hiCD23lo MZ 
B cells from wild type mice [26]. Subsequently, it has been demonstrated that regulatory 
B cells are predominantly contained within a phenotypically unique CD1dhiCD5+ subset 
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in the spleens of naive wild-type mice [29]. Tedder and colleagues termed this specific 
subset of regulatory B cells “B10 cells” to highlight that these rare CD1dhiCD5+ B cells 
only produce IL-10, are responsible for most IL-10 production by B cells, and to 
distinguish them from other regulatory B-cell subsets that may also exist. B10 cells 
share overlapping phenotypic markers with CD5+ B-1a cells, 
CD1dhiCD21hiCD23loIgMhi MZ B cells, and CD1dhiCD21hiCD23hiIgMhi T2-MZ 
precursor (MZP) B cells, but do not exclusively belong to either subset. Additionally, 
B10 cells are quite reminiscent of a dendritic cell-like B-cell subset identified by Burke 
and colleagues in 2004 [30]. These cells display a phenotype of 
B220+CD1d+CD5lo/+CD19+CD11c−CD24hiCD21/35+IgM+IgDlowCD43+CD44hi, secret 
IL-10 in response to culture with Chlamydia trachomatis, and function as APCs for 
cellular immune responses. In 2007, Mauri and colleagues [31] reported that IL-10+ 
cells that can prevent CIA development when adoptively transferred express a 
CD21hiCD23+IgMhiCD1dhiCD93int phenotype, which is similar to that of T2-MZP B 
cells. Thus, regulatory B cells or IL-10-producing B cells described in each of the 
studies share many, if not all, phenotypic markers.  
 
5. Regulatory B cells in disease states  
Studies have elucidated critical roles for regulatory B cells in various murine disease 
models. This review focuses on skin and connective tissue diseases including CHS, 
arthritis, and lupus. Other organ-specific autoimmune disease models, especially EAE 
[17, 18, 32, 33] and colitis [19, 34], have also provided important mechanisms for how 
regulatory B cells work, as have been reviewed in several recent, outstanding review 
articles [2-5]. 
 
5-1. Contact hypersensitivity 
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CHS has been considered as a prototypic Th1 cell-mediated inflammatory reaction 
where B cells are not involved in Ag presentation and thereby have a minimum role, if 
any, in augmenting inflammation. However, we have found that the CHS response is 
significantly exacerbated in CD19-deficient mice where it was expected that B-cell 
hyporesponsiveness would reduce CHS responses (Figure 2) [26]. This led to the 
hypothesis that CD19-defienct mice are defective in regulatory B cells. Indeed, the 
transfer of MZ B cells from wild type mice normalized the augmented CHS in 
CD19-deficient mice. Therefore, while CD19 is a positive regulator in B cell responses, 
the positive regulation provided by CD19 expression is also critical in the regulatory B 
cell subset, and CD19 loss results in a defect in regulatory B cells. These studies were 
extended by showing reduced CHS responses in human CD19 transgenic (hCD19Tg) 
mice that overexpress CD19 and enhanced CHS in wild type mice in which all B cells 
were depleted using CD20 mAbs [29]. The findings that B cells from CD19-deficient 
mice are defective in IL-10 production whereas B cells from hCD19Tg mice 
overproduce IL-10 have led to the identification of the IL-10-producing B cell subset 
responsible for CHS suppression. This splenic B cell subset display CD1dhiCD5+ 
phenotype, as described above. Importantly, IL-10-deficient mice also possess the 
CD1dhiCD5+ B cell population, although the adoptive transfer of IL-10-deficient 
CD1dhiCD5+ B cells does not ameliorate CHS responses, suggesting that this 
suppression is IL-10-dependent. 
B-1 cells in the peritoneal cavity have long been known to be a rich source of 
IL-10, and are also likely to play a role in the suppression of CHS, particularly in the 
late phase [35]. CD22-deficient mice exhibit delayed recovery from CHS reactions 
compared with wild type mice. Adoptive transfer of wild type peritoneal B-1 cells, but 
not IL-10-deifcient peritoneal B-1 cells, reverses the prolonged CHS reaction seen in 
CD22-deificient mice as well as CD19-deficient mice (Figure 2), and this is blocked by 
the simultaneous injection with IL-10 receptor Ab. Thus, two distinct regulatory B cell 
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subsets cooperatively inhibit CHS responses. While splenic CD1dhiCD5+ B cells have a 
crucial role in suppressing the acute exacerbating phase of CHS, peritoneal B-1a cells 
are likely to suppress the late remission phase, although their role appears less 
significant compared with that of splenic B10 cells. CD22 deficiency may result in 
disturbed CHS remission by impaired retention or survival of peritoneal B-1a cells that 
migrate into lymphoid organs. 
 The role of B-1 cells in CHS is still controversial, however. While our study, 
as described above [35], suggests that B-1 cells have a protective role, Tsuji and 
colleagues demonstrate a promoting, rather than inhibitory, role for peritoneal B-1 cells 
in CHS [36]. Using Btk-defective xid mice on a CBA background, they demonstrated 
that Ag-specific IgM Abs from peritoneal B-1 cells are required for the recruitment of 
effector T cells in the early elicitation phase [36]. The discrepancy between these results 
may be due to the differences in mouse genetic backgrounds and/or haptens. Also, it is 
possible that peritoneal B-1 cells have both promoting and suppressive roles in CHS. 
Ultraviolet (UV) exposure is known to suppress a wide variety of immune 
reactions including CHS, and may do so, in part, through activation of regulatory B 
cells. Matsumura et al. reported that transferring lymph nodes cells from UV-irradiated, 
FITC-sensitized mice into normal recipients induces immune tolerance [37]. Notably, 
the cell responsible is an FITC+CD19+B220+ IL-10-secreting B cell. In this study, 
platelet-activating factor and serotonin were found to be necessary for the activation of 
immunoregulatory B cells [37]. These findings are supported by the data from Byrne 




B cells are considered pathogenic in rheumatoid arthritis (RA). While the precise 
mechanisms of B cell-mediated pathogenesis of human RA remain unclear, B 
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cell-depletion therapy using Rituximab has been shown to be effective. B cells are also 
important for initiating inflammation in mouse RA models. Mathis, Benoist, and 
colleagues have established the K/BxN mouse model, in which a disease with most of 
the clinical, histologic, and immunologic features of RA spontaneously develops due to 
the secretion of arthritogenic Ig, However, they also observed that B cell–deficient mice 
injected with arthritogenic Ig develop more severe arthritis, suggesting that B cells may 
have an inhibitory effect [39]. Mauri and colleagues have demonstrated a protective role 
for B cells in CIA, in addition to their previously known pathogenic role [20]. They 
have shown that when arthritogenic B cells are stimulated with anti-CD40 mAb and 
collagen they produce IL-10, and that B cells stimulated with anti-CD40 mAb and 
collagen from arthritogenic mice, when adoptively transfered into syngeneic immunized 
recipient mice, prevented the induction of arthritis and ameliorated established disease. 
This regulatory function of B cells depends on the production of IL-10, as transfer of 
T2-MZP B cells isolated from IL-10-deficient DBA mice fail to protect recipient mice 
from developing arthritis [31]. IL-10-producing B cells display a 
CD1dhiCD21hiCD23+IgM+ phenotype, which is consistent with T2-MZP B cells. The 
numbers of IL-10-producing T2-MZP B cells, present in naïve mouse spleens, decrease 
at the peak of inflammation and increase during the remission phase of CIA. The 
adoptive transfer of T2-MZP B cells, but not follicular B cells or MZ B cells, derived 
from arthritogenic mice in remission phase, prevented CIA and reduced disease severity. 
Moreover, the adoptive transfer of T2-MZP B cells from naive mice also had a 
significant but less dramatic effect on CIA progression. 
Another study demonstrated that administering apoptotic thymocytes to mice 
before the clinical onset of CIA is protective for joint inflammation and bone 
destruction [40]. Activated splenic B cells responded directly to apoptotic cell treatment 
by increasing secretion of IL-10, which is important for inducing T-cell-derived IL-10. 
Moreover, the passive transfer of B cells from apoptotic cell-treated mice provided 
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significant protection from arthritis. Inhibition of IL-10 in vivo reversed the beneficial 
effects of apoptotic cell treatment. Thus, apoptotic cells can induce regulatory B cells, 




B cells play several critical roles in the pathogenesis of systemic lupus erythematosus 
(SLE). In lupus, it is now apparent that regulatory B cells are important for the disease 
suppression (Figure 3). We have examined the role of regulatory B cells in the New 
Zealand Black and New Zealand White F1 hybrid (NZB/W) mouse model [41]. In 
NZB/W mice deficient for CD19 the emergence of anti-nuclear Abs was significantly 
delayed compared with wild type NZB/W mice. However, the pathologic manifestations 
of nephritis appeared significantly earlier, and survival was considerably reduced in 
CD19-deficient NZB/W mice compared with wild type mice. These results demonstrate 
both disease-promoting and protective roles for B cells in lupus pathogenesis. In wild 
type NZB/W mice, the CD1dhiCD5+B220+ B cell subset that includes B10 cells was 
increased by 2.5-fold during the disease course, whereas CD19-deficient NZB/W mice 
lacked this CD1dhiCD5+ regulatory B cell subset. Furthermore, the transfer of splenic 
CD1dhiCD5+ B cells from wild type NZB/W mice into CD19-deficient NZB/W 
recipients significantly prolonged their survival. Intriguingly, regulatory T cells were 
significantly decreased in CD19-deficient NZB/W mice, and the transfer of wild type 
CD1dhiCD5+ B cells induced T regulatory cell expansion in CD19-deficient NZB/W 
mice. Thus, regulatory B10 cells play an important protective role in lupus. 
That distinct B cell populations have opposing protective and pathogenic roles 
during lupus progression is directly shown by our experiments in which CD20 mAb 
treatment initiated in 12–28-week-old NZB/W F1 mice, and administered every 4 
weeks thereafter, significantly delays spontaneous disease [42]. By contrast, B cell 
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depletion initiated in 4-week-old mice hastens disease onset. This is especially 
important when considering the efficacy of B cell-targeted therapy in lupus since 
pan-B-cell depletion therapies may be a double-edged sword for some patients.  
Mauri and colleagues, using MLR/lpr mice, demonstrated that transfer of in 
vitro anti-CD40-generated T2 MZP B cells significantly improves renal disease and 
survival by an IL-10-dependent mechanism, while transfer of unmanipulated T2 B cells, 
isolated from mice with established lupus, are not able to confer protection to diseased 
mice [43]. Anti-CD40-treated T2 MZP B cells accumulate in the spleen after transfer, 
and induce the differentiation of IL-10+ CD4+ T cells. In addition, in vivo administration 
of agonistic anti-CD40 Ab halts and reverses established lupus. Collectively, these 
studies demonstrate the importance of protective role for regulatory B cells in lupus. 
 
6. Regulatory B cells in humans 
In comparison to the accumulation of data relating to mouse regulatory B cells, little is 
known regarding human regulatory B cells. However, it has been demonstrated that 
human B cells can produce IL-10 [44]. Human tonsil B cells costimulated with CpG 
ODNs and CD40 ligand (CD40L) have a high proliferative response and produce large 
quantities of IL-10. Interestingly, CD40 activation of human B cells associated with 
TLR stimulation promotes the production of IL-10 [45]. Peripheral blood B cells from 
patients with SLE, RA, and primary Sjögren Syndrome transcribe constitutively higher 
levels of messenger RNA for IL-10 as compared with controls [46]. Another study 
showed that peripheral blood B cells from SLE patients constitutively secrete more 
IL-10 in vitro than those from normal controls on both a per-cell and a percentage basis. 
This production of IL-10 is associated with expression of CD40L, suggesting that 
cellular activation is a prerequisite for the production of IL-10 [47]. While CD5+ B cells 
from SLE patients are reported to produce high levels of IL-10 [48], contrasting data 
show that IL-10–producing B cells in SLE do not belong to the CD5 population, but 
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rather, to a population of activated CD40L+ B cells [47]. 
Recently, Blair et al. have demonstrated that human CD19+CD24hiCD38hi B 
cells possess regulatory capacity [49]. After CD40 stimulation, CD19+CD24hiCD38hi B 
cells suppressed the differentiation of Th1 cells, partially via the provision of IL-10, but 
not transforming growth factor- (TGF-), and their suppressive capacity was reversed 
by the addition of CD80 and CD86 mAbs. In addition, CD19+CD24hiCD38hi B cells 
isolated from the peripheral blood of SLE patients were refractory to further CD40 
stimulation, produced less IL-10, and lacked the suppressive capacity of their healthy 
counterparts. Interestingly, their study suggests that, in contrast to murine regulatory B 
cells, the suppressive activity of human regulatory B cells is only partially dependent on 
IL-10. One possibility is cell-cell contact, in which interactions between B cells and 
CD4+ T cells mediated through CD80/CD86 and CD28/CTLA-4 may work 
synergistically with B cell IL-10 production to suppress CD4+ T cell cytokine 
production. By contrast, Tedder and colleagues consider that B10 and progenitor B10 
cells are predominantly found within the CD24hiCD27+ B cell subpopulation (Dr. 
Thomas F. Tedder, personal communication). Thus, it is highly likely that regulatory B 
cells also exist in humans, while the cell-surface phenotype of regulatory B cells is yet 
to reach consensus. 
Finally, B cell-depletion therapy also suggests the existence of regulatory B 
cells in humans and their relevance to skin diseases. Recent reports describe patients 
who developed psoriasis following treatment with rituximab for rheumatoid arthritis 
[50]. While this is not definitive evidence for their existence, it is intriguing to speculate 
that regulatory B cells may be involved in a variety of skin and connective tissue 
diseases in human other that those described above.  
While the importance of regulatory B cells is emerging, many questions 
remain. Identifying the definitive markers of regulatory B cells and clarifying the 
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molecular mechanisms by which regulatory B cells suppress immune responses will be 
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Figure 1. Development and phenotypic markers of B-2 cell lineage in mouse 
 
Figure 2. Two regulatory B cell subsets suppress contact hypersensitivity (CHS).  
(A) Wild type and CD19-deficient (CD19-/-) mice were sensitized with 0.5% DNFB for 
2 consecutive days. Five days later, CHS was elicited by 0.25% DNFB on the right ear. 
Ear thickness was measured on the day of challenge and for 10 days post challenge. (B) 
Splenic follicular B cells (yellow bars), sera (green bars), splenic marginal zone B cells 
including B10 cells (red bars), or peritoneal B-1 cells (blue bars) from wild type mice 
were transferred to CD19-/- mice. CHS was elicited by DNFB 1 day after transfer. *, 
P<0.05, **, P<0.01. 
 
Figure 3. Pathogenic and protective roles of B cells in systemic lupus erythematosus 
(SLE). 
B cells have pathogenic roles in SLE via autoantibody production, cytokine secretion, 
and antigen presentation. On the other hand, regulatory B cells exert a protective 
activity via IL-10 production, which may affect regulatory T cell functions. 
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